Gossamer Bio Q1 net loss $49.2M; advancing seralutinib to Phase 3 in PAH

Gossamer Bio, Inc.

2023-Q1 EPS reported -$0.52

Net loss of $49.2M ($0.52 per share) for Q1 2023 vs. $57.8M ($0.76) in Q1 2022.
Cash, equivalents and marketable securities of $201.9M as of March 31, 2023; expected to fund operations through at least 12 months.
Phase 3 registrational trial of seralutinib in PAH planned for 3Q23; FDA and EMA feedback on key design elements received.
Operational restructuring: headcount reduced by over 25%; all other clinical/preclinical programs terminated.
Initial open-label extension data from TORREY study expected mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Gossamer Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share.

Period: the quarter ended March 31, 2023
Net income: Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share
Result: reported results

Exact text from the filing

On May 9, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-23-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.